$0.67
-0.02 (-2.61%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where APRE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 8 with posted results
Held by 3 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of APR-1051 in Patients With Advanced Solid TumorsNCT06260514Treatment-related adverse eventsOpen-label · Treatment | Phase 1 | Recruiting | Drug: APR-1051 | Advanced Solid Tumor | 90 | Jun 2027 | ≤ 315 d | 2026-08-17 |
| Study Of ATRN-119 In Patients With Advanced Solid TumorsNCT04905914Treatment Emergent Adverse Events (TEAEs) will be collected and evaluated based on summary statisticsNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: ATRN-119 | Advanced Solid Tumor | 43 | 2026-03-09actual | — | 2026-08-04 |
| Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesNCT04383938results2025-05-13To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors.Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: APR-246 (eprenetapopt) + Pembrolizumab | Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor | 40 | 2022-04-30actual | — | 2025-05-13 |
| APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)NCT04638309results2025-03-07To Investigate the "Number of Participants With Treatment Emergent Adverse Events From Treatment With APR-548 as Monotherapy and in Combination With AzacitidineNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: APR-548 + Azacitidine | MDS, Myelodysplastic Syndromes | 4 | 2022-04-25actual | — | 2025-03-10 |
| APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid MalignanciesNCT04214860results2025-02-21To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in Patients With TP53 Mutant Myeloid Malignancies.Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: APR-246, Venetoclax, Azacitidine | Myeloid Malignancy | 51 | 2022-01-14actual | — | 2025-03-17 |
| APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell TransplantNCT03931291results2024-03-26To Assess Relapse-free Survival (RFS) in Patients With TP53 Mutated AML or MDS After Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT).Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: APR-246 | Acute Myeloid Leukemia or Myelodysplastic Syndromes | 33 | 2021-08-27actual | — | 2025-03-17 |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)NCT04419389results2024-11-15To Determine the DLT of APR-246 in Combination With Acalabrutinib or in Combination With Venetoclax + Rituximab Therapy in Subjects With NHL, Including Subjects With R/R CLL, RT and R/R MCL.Non-randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT | Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | 1 | 2021-08-23actual | — | 2025-03-17 |
| APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)NCT03745716results2022-07-12Complete Response Rate (CR)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: APR-246 + azacitidine, Azacitidine | MDS | 154 | 2020-11-27actual | — | 2025-03-18 |
| p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246NCT03268382results2022-07-21Overall Response Rate (ORR)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: APR-246, Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | High-grade Serous Ovarian Cancer | 36 | 2019-07-10actual | — | 2025-03-17 |
| p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246NCT02098343results2022-09-21Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD RegimenRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 | 247 | Apr 2019actual | — | 2025-03-17 |
| A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant MelanomaNCT03391050Phase Ib: Adverse Events (AEs)Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Target patient population - difficult to find patientes | Drug: APR-246, Dabrafenib | Melanoma | 3 | 2018-08-08actual | — | 2019-07-31 |
| Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate CancerNCT00900614Dose-Limiting Toxicity (DLT) is reached and HFD is defined accordingly, OR the dose, which is expected to result in maximum plasma concentration close to, but not exceeding 35 μg/ml in any single patient without showing signs of DLT.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: APR-246 | Hematologic Neoplasms, Prostatic Neoplasms | 36 | Oct 2010actual | — | 2019-07-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19